Repligen, a bioprocessing tech firm, showed a 15% revenue increase in Q1 2026, signaling recovery after a challenging 2024. The company focuses on margin expansion and higher-value portfolio areas, supported by a strong balance sheet and good cash flow for potential growth and acquisitions, especially in Asia. However, its high valuation poses a risk with limited safety margin for investors. Execution remains critical despite improvements in business segments like Polymem and China operations.
Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and a disease control rate of 52%. The 160 mcg dose demonstrated better clinical outcomes and...
Apple's stock surged 15% in May, driven by optimism around its future in AI, particularly the potential of 'agentic smartphones.' Bank of America raised Apple's price target to $380, highlighting this AI opportunity as a key growth driver. Meanwhile,...
Victoria Hanrahan, a senior executive at Nokia, acquired a total of 44,682 Nokia shares on May 26 and May 28, 2026. The shares were purchased on the New York Stock Exchange at average prices of $16.02 and $15.60 respectively, with a combined average ...
Victoria Hanrahan, a senior manager at Nokia Corporation, purchased a total of 44,682 shares on May 26 and May 28, 2026. The shares were acquired on the New York Stock Exchange at an average price of $15.81 per share. This transaction signals confide...
MicroStrategy's recent Bitcoin purchase signals strong institutional confidence and reduces chances of near-term sales by the company. Market predictions show a 99.8% probability that Bitcoin's price will stay above $78,000 on June 1, 2026. This move...
